Strides Pharma gets FDA nod for Mycophenolate Mofetil, targets $145m market

Strides Pharma gets FDA nod for Mycophenolate Mofetil, targets $145m market

Strides Pharma Science Limited has announced a significant win as its Singapore-based wholly owned subsidiary, Strides Pharma Global Pte. Limited, has received United States Food & Drug Administration (FDA) approval for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. The product is bioequivalent and therapeutically equivalent to CellCept for Oral Suspension by Roche Palo Alto, […]